Your browser is no longer supported. Please, upgrade your browser.
ARCA biopharma, Inc.
Index- P/E- EPS (ttm)-2.65 Insider Own0.40% Shs Outstand9.32M Perf Week-10.63%
Market Cap42.43M Forward P/E- EPS next Y- Insider Trans260.16% Shs Float9.28M Perf Month4.55%
Income-5.80M PEG- EPS next Q- Inst Own8.90% Short Float1.29% Perf Quarter4.30%
Sales- P/S- EPS this Y59.80% Inst Trans4.47% Short Ratio0.13 Perf Half Y-14.31%
Book/sh8.35 P/B0.52 EPS next Y- ROA-29.30% Target Price- Perf Year16.84%
Cash/sh5.26 P/C0.83 EPS next 5Y- ROE-31.30% 52W Range2.21 - 22.00 Perf YTD8.98%
Dividend- P/FCF- EPS past 5Y41.30% ROI- 52W High-79.25% Beta2.77
Dividend %- Quick Ratio34.00 Sales past 5Y- Gross Margin- 52W Low106.56% ATR0.33
Employees9 Current Ratio34.00 Sales Q/Q- Oper. Margin- RSI (14)48.61 Volatility7.15% 6.76%
OptionableYes Debt/Eq0.00 EPS Q/Q56.70% Profit Margin- Rel Volume2.29 Prev Close4.37
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume930.93K Price4.57
Recom- SMA20-3.85% SMA501.89% SMA200-13.27% Volume802,448 Change4.46%
Feb-27-18Initiated Ascendiant Capital Markets Buy $2
Oct-09-13Initiated Dawson James Buy $3.75
Feb-13-21 01:09AM  
Dec-15-20 08:30AM  
Dec-09-20 05:40PM  
Nov-23-20 12:28PM  
Nov-02-20 08:30AM  
Oct-07-20 08:30AM  
Oct-05-20 04:30PM  
Sep-21-20 08:00AM  
Aug-17-20 08:49AM  
Aug-12-20 08:00AM  
Aug-05-20 04:15PM  
Jul-07-20 08:30AM  
Jun-03-20 09:56AM  
Jun-01-20 08:20AM  
May-29-20 12:24PM  
May-28-20 04:19PM  
May-07-20 08:30AM  
May-06-20 04:30PM  
Feb-18-20 04:30PM  
Feb-01-20 08:31AM  
Nov-06-19 04:10PM  
Nov-03-19 08:47AM  
Sep-12-19 08:30AM  
Sep-11-19 08:30AM  
Sep-04-19 01:37PM  
Aug-21-19 09:49AM  
Aug-01-19 04:30PM  
Jun-04-19 07:09AM  
May-13-19 09:00AM  
May-08-19 04:30PM  
May-01-19 08:30AM  
Apr-23-19 08:30AM  
Mar-18-19 08:30AM  
Mar-06-19 08:00AM  
Feb-27-19 04:15PM  
Feb-20-19 07:30AM  
Jan-16-19 08:30AM  
Dec-26-18 11:47AM  
Dec-20-18 04:01PM  
Nov-14-18 04:30PM  
Nov-12-18 08:30AM  
Nov-05-18 08:30AM  
Oct-10-18 04:16PM  
Oct-02-18 08:00AM  
Sep-18-18 08:30AM  
Aug-09-18 04:15PM  
Aug-03-18 09:45AM  
Jul-31-18 12:15PM  
Jun-19-18 07:05AM  
May-29-18 08:30AM  
May-11-18 08:20AM  
May-10-18 08:30AM  
May-08-18 04:15PM  
Apr-23-18 08:30AM  
Apr-03-18 07:20AM  
Mar-22-18 04:30PM  
Feb-27-18 03:00PM  
Feb-26-18 02:18PM  
Jan-23-18 05:13PM  
Jan-08-18 08:30AM  
Jan-02-18 05:09PM  
Dec-08-17 06:13PM  
Nov-30-17 02:25PM  
Nov-20-17 08:05AM  
Nov-17-17 08:10AM  
Nov-16-17 08:30AM  
Nov-09-17 04:05PM  
Oct-23-17 08:16PM  
Sep-21-17 08:30AM  
Aug-16-17 08:30AM  
Aug-09-17 04:30PM  
Aug-03-17 04:15PM  
Jun-20-17 08:30AM  
May-15-17 08:30AM  
Apr-26-17 08:30AM  
Apr-18-17 08:30AM  
Mar-25-17 01:04PM  
Mar-21-17 04:46PM  
Mar-06-17 04:32PM  
Mar-01-17 04:47PM  
Feb-21-17 08:46AM  
Jan-18-17 04:32PM  
Jan-11-17 04:54PM  
Jan-04-17 08:30AM  
Dec-20-16 02:26PM  
ARCA biopharma, Inc. operates as a biopharmaceutical company applying a precision medicine approach to developing and commercializing genetically targeted therapies for cardiovascular diseases. Its lead product candidate, Gencaro (bucindolol hydrochloride) is pharmacogenetically-targeted beta-adrenergic receptor antagonist, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF). The company also engages in the development of AB171, a thiol-substituted isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CONWAY ROBERT EChairman of the BoardDec 18Buy4.1610,00041,63030,000Dec 21 04:15 PM
CONWAY ROBERT EChairman of the BoardSep 25Buy4.285,00021,39920,000Sep 25 04:20 PM
CONWAY ROBERT EChairman of the BoardSep 22Buy4.663,05614,24115,000Sep 24 04:20 PM
CONWAY ROBERT EChairman of the BoardSep 21Buy4.7710,00047,66011,944Sep 21 05:00 PM